Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pegah Bikdeli"'
Autor:
Sara Khoshroo, Saleh Sandoughdaran, Parisa Sabetrasekh, Parastoo Hajian, Pegah Bikdeli, Parto Sabetrasekh, Fatemeh Nasrollahi, Ladan Mohammadi Yeganeh, Sepideh Jafari Naeini, Hamid Reza Mirzaei
Publikováno v:
International Journal of Breast Cancer, Vol 2021 (2021)
Background/Aims. The anthracycline and taxane-based chemotherapy regimens are the standard adjuvant treatment of node-positive breast cancer patients. Although it was believed that docetaxel and paclitaxel are similarly effective as adjuvant treatmen
Externí odkaz:
https://doaj.org/article/a25ba2050e2a4aa8b025b0e5a2ad007d
Autor:
Parto Sabetrasekh, Saleh Sandoughdaran, Ladan Mohammadi Yeganeh, Fatemeh Nasrollahi, Sara Khoshroo, Parastoo Hajian, Pegah Bikdeli, Hamid Reza Mirzaei, Sepideh Jafari Naeini, Parisa Sabetrasekh
Publikováno v:
International Journal of Breast Cancer
International Journal of Breast Cancer, Vol 2021 (2021)
International Journal of Breast Cancer, Vol 2021 (2021)
Background/Aims. The anthracycline and taxane-based chemotherapy regimens are the standard adjuvant treatment of node-positive breast cancer patients. Although it was believed that docetaxel and paclitaxel are similarly effective as adjuvant treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5e32fca80ffdb3ff56c07d12d8f6106
Autor:
Mohammad Imani, Mohsen Ahmadi, Hossein Ahmadi, Morteza Daliri, Payam Mohammadinejad, Pegah Bikdeli, Abbas Salehi Omran, Mehdi Najafi, Farhad Fathi, Armita Mahdavi, Abbasali Karimi Karimi
Publikováno v:
International Journal of Hospital Research. 5:22-28
Background and Objectives: Complete revascularization is not possible in up to 37% of patients with coronary artery disease (CAD). Therapeutic angiogenesis may be considered as an option in the management of these patients. The aim of the present stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98540fba2c359fa16b5db5d8c3490541
https://doi.org/10.15171/ijhr.2016.05
https://doi.org/10.15171/ijhr.2016.05
Autor:
Parastoo Hajian, Sepideh Jafari Naeini, Pegah Bikdeli, Ladan Mohammadi Yeganeh, Hamid Reza Mirzaei, Fatemeh Nasrollahi
Publikováno v:
Chemotherapy Research and Practice
Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined. Objectives. The feasibility of dose-dense
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2258b8e978e99e0539d7b3c1ed55ad3f
https://doi.org/10.1155/2014/259312
https://doi.org/10.1155/2014/259312